Skip to main content

Table 4 Characteristics of patients with stage II pure mucinous carcinoma of the breast

From: Pure mucinous carcinoma of the breast: clinicopathologic characteristics and long-term outcome among Taiwanese women

   Endocrine therapy P
   With chemotherapy (n = 30) Without chemotherapy (n = 15)  
Age, years    0.001
  mean (SD) 43.43 (6.17) 61.16 (16.89)  
  median 44.68 64.20  
  range 31.0, 57.0 28.0, 84.0  
Tumor size, cm    0.772
  mean (SD) 3.60 (2.89) 3.34 (2.43)  
  median 3.0 2.8  
  range 0.20, 17.0 2.0, 12.0  
Tumor stage, n (%),    0.545
  T1 2 (7.14) 0 (0)  
  T2 26 (92.86) 14 (100)  
  unknown or other 2 1  
Grade, n (%),    1.000
  I 9 (81.82) 3 (75)  
  II 2 (18.18) 1 (25)  
  unknown or other 19 11  
Lymphovascular invasion, n (%),    0.624
  present 4 (21.05) 1 (8.33)  
  absent 15 (78.95) 11 (91.67)  
  unknown or other 11 3  
ER status, n (%),    1.000
  positive 28 (93.33) 14 (93.33)  
  negative 2 (6.67) 1 (6.67)  
PR status, n (%),    0.695
  positive 23 (76.67) 13 (86.67)  
  negative 7 (23.33) 2 (13.33)  
HER2 status, n (%),    1.000
  positive 1 (3.70) 1 (7.14)  
  negative 26 (96.30) 13 (92.86)  
  unknown or other 3 1  
Lymph node status (%)    0.396
  positive 6 (20) 1 (6.67)  
  negative 24 (80) 14 (93.33)  
Primary treatment, n (%),    1.000
  mastectomy 23 (76.67) 11 (73.33)  
  lumpectomy with RT 7 (23.33) 4 (26.67)  
Follow up time, months    
  median 57 43  
  range 3, 139 12, 86  
10-year disease-free survival 87.69% 75% 0.637
10-year overall survival rate 88.44% 100% 0.424
  1. ER estrogen receptor, PR progesterone receptor, RT radiotherapy.